Alumis reported positive Phase III results for envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints in two pivotal trials for moderate-to-severe plaque psoriasis. The company said the drug achieved high rates of skin clearance at week 16, prompting a substantial market reaction and plans to pursue regulatory filings. BioCentury and market reports detailed trial performance and comparative efficacy versus other oral TYK2 and JAK/TYK2 competitors, positioning envudeucitinib among the leading oral therapies. Alumis’ leadership characterized the data as a pivotal value inflection and signaled intent to move toward approvals and commercialization planning. Investors reacted immediately, sending Alumis shares sharply higher and underscoring the market’s sensitivity to late‑stage dermatology readouts that can reorder oral biologic competition.